Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient

被引:0
|
作者
Franceschini, Gianluca [1 ]
Di Leone, Alba [1 ]
Sanchez, Alejandro Martin [1 ]
D'Archi, Sabatino [1 ]
Terribile, Daniela [1 ]
Magno, Stefano [1 ]
Scardina, Lorenzo [1 ]
Masetti, Riccardo [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli, Dept Woman Child & Publ Hlth, IRCCS,Div Breast Surg, Largo Agostino Gemelli 8, I-00168 Rome, Italy
关键词
Axillary treatment; Breast cancer; Neoadjuvant chemotherapy; Sentinel lymph node biopsy; AXILLARY DISSECTION; MANAGEMENT;
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Today, sentinel lymph node biopsy (SLNB) is considered the gold standard for axillary staging in early breast cancer patients with clinically negative lymph nodes (cNO). SLNB allows to determine the axillary lymph node status sparing the axillary dissection (AD) and its potential complications (seroma formation, loss of sensation, shoulder dysfunction and lymphedema) On the other hand, SLNB for nodal staging in breast cancer patients with clinically negative lymph nodes after neoadjuvant chemotherapy (ycN0) is a highly debated topic due to different reported success rates. In order to optimize oncological results, high identification rate (> 90%) and false negative rate as low as possible (< 10%) should always be obtained when performing SLNB after neoadjuvant chemotherapy. The success rates of SLNB after neoadjuvant chemotherapy (NAC) mainly depend on the clinical lymph node status pre-NAC. In patients with pre-NAC clinically negative nodes (cN0) and at restaging with post-NAC clinically negative nodes (ycN0), SLNB after chemotherapy should be performed because it is an accurate and safe procedure. In patients with pre-NAC clinically positive nodes (cN+) and at restaging with post-NAC clinically negative nodes (ycN0), SLNB after chemotherapy might be considered thanks to the high lymph nodal pathologic complete response rate; however, in this last setting, individual ability, technical skills and repetitive performance of specific tasks must always be followed to improve the identification rate and false negative rate. AD may be avoided only if sentinel lymph node is negative [ypN0(sn)J; instead, to date, patients with metastatic sentinel lymph node after neoadjuvant chemotherapy, even with only isolated tumor cells, fypN+(sn) including ypN0i+(sn) and ypN1mic(sn)J should always be treated with AD. However, NAC significantly increases the difficulties and complexity of axillary surgical management. A personalized multidisciplinary path in specialized breast centers should ensure an accurate clinical counselling and refined patient selection for SLNB post-NAC.
引用
收藏
页码:465 / 468
页数:4
相关论文
共 50 条
  • [21] Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer
    Conti, A.
    Ferraris, C.
    Gennaro, M.
    Zambetti, M.
    Greco, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 106 - 106
  • [22] Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer
    Julian, TB
    Dusi, D
    Wolmark, N
    AMERICAN JOURNAL OF SURGERY, 2002, 184 (04): : 315 - 317
  • [23] Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 75 - 75
  • [24] Sentinel lymph node biopsy after neoadjuvant chemotherapy
    不详
    BREAST, 2005, 14 : S43 - S43
  • [25] Sentinel lymph node biopsy after neoadjuvant chemotherapy
    Kang S.H.
    Kang J.H.
    Chow E.A.
    Lee E.S.
    Breast Cancer, 2004, 11 (3) : 233 - 241
  • [26] Analysis of sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.
    Jinno, H
    Ikeda, T
    Kitajima, M
    Fujii, H
    Mukai, M
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S41 - S41
  • [27] Sentinel lymph node biopsy in breast cancer: the role of ICG fluorescence after neoadjuvant chemotherapy
    Bogacz, Pawel
    Pelc, Zuzanna
    Mlak, Radoslaw
    Sedlak, Katarzyna
    Kobialka, Sebastian
    Mielniczek, Katarzyna
    Lesniewska, Magdalena
    Chawrylak, Katarzyna
    Polkowski, Wojciech
    Rawicz-Pruszynski, Karol
    Kurylcio, Andrzej
    BREAST CANCER RESEARCH AND TREATMENT, 2025, : 699 - 707
  • [28] Role of micrometastases in sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients
    Ponce, J.
    Delgado, S.
    Ballester, H.
    Martin, T.
    Peiro, G.
    Montoyo-Pujol, Y. G.
    Garcia-Escolano, M.
    Aranda, F.
    Niveiro, M.
    Reche, M.
    Rodriguez-Lescure, A.
    Lozano, I.
    Massuti Sureda, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S323 - S323
  • [29] USE OF FLUORESCENCE FOR SENTINEL LYMPH NODE BIOPSY AFTER NEOADJUVANT CHEMOTHERAPY IN INFLAMMATORY BREAST CANCER
    Kaabia, O.
    Bouchahda, R.
    Bibi, M.
    Hidar, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A35 - A35
  • [30] Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer
    Wong, Stephanie M.
    Basik, Mark
    Florianova, Livia
    Margolese, Richard
    Dumitra, Sinziana
    Muanza, Thierry
    Carbonneau, Annie
    Ferrario, Cristiano
    Boileau, Jean Francois
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (05) : 2621 - 2629